EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience

David C Hutchings iD, Christopher P Denton, Luigi Venetucci, Andrew W Trafford iD

Experimental Physiology · 2025

DOI: 10.1113/ep092932 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Experimental Physiology, 2025. Verfasst von David C Hutchings und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cardiac Physiology, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre,…. Hauptthemen laut MEDLINE: Ventricular Premature Complexes, Phosphodiesterase 5 Inhibitors, Sulfones, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phosphodiesterase‐5 inhibitor sildenafil suppresses ventricular arrhythmias in a sheep model of drug‐induced long QT. In that study, ventricular arrhythmias were abolished by reducing premature ventricular complexes (PVCs) and delaying PVC onset, thus preventing ‘R‐on‐T’ ventricular tachycardia. Evidence for effects in humans with arrhythmias is lacking. In this case study, a 50‐year‐old female with a history of PVCs and systemic sclerosis was started on sildenafil for Raynaud's phenomenon in line with current treatment recommendations. During initiation, the patient wore a 7‐day cardiac monitor. Two subtypes of PVCs were observed: one distinct morphology arising 400 ms from the preceding sinus beat (‘late’). Sildenafil abolished late PVCs and substantially reduced the frequency of early PVCs. Of those early PVCs remaining during sildenafil treatment, PVCs arose later in the cardiac cycle, 21 ms further from the preceding T wave apex. During washout, PVCs returned in frequency and timing towards baseline values. We report the first case suggesting an anti‐arrhythmic property of sildenafil in a human.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ventricular Premature ComplexesPhosphodiesterase 5 InhibitorsSulfonesPiperazinesSildenafil CitrateHumansFemaleMiddle AgedPurinesElectrocardiography

Stichwörter der Autor:innen

arrhythmiaphosphodiesterase‐5sildenafil

Substanzen

Sildenafil CitratePhosphodiesterase 5 InhibitorsSulfonesPurinesPiperazines

Autor:innen und Institutionen

  • Unit of Cardiac Physiology, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, 3.24 Core Technology Facility, University of Manchester, Manchester,…
  • Centre for Rheumatology, Royal Free Campus, NW3 2PS, University College London, London, UK.

ORCID-Profile: David C Hutchings, Andrew W Trafford

Förderung

  • British Heart Foundation

Zitieren

APA

Hutchings, D. C., Denton, C. P., Venetucci, L., & Trafford, A. W. (2025). Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience. Experimental Physiology. https://doi.org/10.1113/ep092932

Vancouver

Hutchings DC, Denton CP, Venetucci L, Trafford AW. Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience. Experimental Physiology. 2025. doi:10.1113/ep092932

BibTeX
@article{Hutchings2025,
  author = {Hutchings, David C and Denton, Christopher P and Venetucci, Luigi and Trafford, Andrew W},
  title = {Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience},
  journal = {Experimental Physiology},
  year = {2025},
  doi = {10.1113/ep092932}
}
Kostenlos starten →